Accord Healthcare Simvastatin 80 mg Tablets Recalled for Manufacturing Practice Violations
Accord Healthcare is recalling Simvastatin 80 mg tablets due to manufacturing practice deviations discovered during an FDA inspection. Approximately 205,631 bottles are affected across the US, Puerto Rico, and Canada.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for manufacturing practice deviations that could affect drug quality and safety. No illnesses or injuries have been reported, but the potential for harm from compromised manufacturing processes warrants the High rating.
Plain-English summary
Accord Healthcare, Inc. is recalling Simvastatin (SIMVASTATIN) 80 mg tablets due to Current Good Manufacturing Practice (CGMP) deviations discovered during an FDA inspection. CGMP violations indicate manufacturing processes that do not meet federal standards for ensuring drug quality, purity, strength, and safety.
The recall involves approximately 205,631 bottles distributed across the United States, including Puerto Rico and Canada. The affected products include 90-count bottles (NDC 16729-007-15) and 1,000-count bottles (NDC 16729-007-17). These tablets were manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India, and are distributed by Accord Healthcare, Inc., based in Durham, North Carolina.
The recall encompasses multiple batch numbers with expiration dates ranging from February 2023 through April 2025. Patients currently taking this medication should consult their healthcare provider for guidance.
The recalled product
- Product
- SIMVASTATIN (SIMVASTATIN)
- Brand
- SIMVASTATIN
- Manufacturer
- Accord Healthcare, Inc.
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) R2100387
- R2100393
- Exp. Date 2/28/2023
- P2102556
- P2102558
- P2102636
- Exp. Date 4/30/2023
- P2103981
- P2103877
- P2103958
- Exp. Date 5/31/2023
- R2101393
- R2101395
- R2101394
- Exp. Date 10/31/2023
- P2202681
- P2202653
- Exp. Date 4/30/2025
- b)R2000555
- R2000587
UPCs (2)
- 316729007153
- 316729007177
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · SIMVASTATIN
- HighSimvastatin 40 mg tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighPrescription Drug Simvastatin Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateSimvastatin Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- ModerateSimvastatin tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27